Infant Gut Microbiome Maturation With SCFA-Producing Bacteria
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The challenge of maintaining a healthy microbiome in infants, particularly those with dysbiosis, is addressed by the use of specific bacterial strains and mammalian milk oligosaccharides to increase short-chain fatty acids (SCFA) production, reduce pathogenic bacteria, and lower inflammation.
Innovation Solution
Administering a bacterial composition capable of colonizing the colon, combined with mammalian milk oligosaccharides (MMO), to promote a healthy microbiome by increasing SCFA levels, specifically acetate and lactate, and reducing pathogenic bacteria and inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional teaching is followed to maintain diversity of microorganisms in the microbiome, then microbiome complexity is improved, but this does not address the specific need for healthy microbiome development in infants with dysbiosis
Solution Approach 1:
The patent segments the microbiome development process into distinct phases: initial colonization with specific bacterial strains (Bifidobacterium, Lactobacillus, Streptococcus) followed by gradual introduction of diversity through mammalian milk oligosaccharides. This segmented approach ensures reliable healthy development while building complexity systematically rather than attempting to maintain all diversity simultaneously.
Solution Approach 2:
The patent applies preliminary action by first establishing a foundation of beneficial bacteria and SCFA production capacity before introducing diverse microorganisms. The infant microbiome is pre-conditioned with specific bacterial strains that produce acetate and lactate, creating a stable base that supports subsequent diversity while ensuring health reliability from the outset.
2Reliability
If bacterial composition and MMO are administered to increase SCFA levels, then microbiome health is improved, but the complexity of the microbiome may be reduced
Solution Approach 1:
The patent implements periodic action by administering bacterial compositions and mammalian milk oligosaccharides in a structured sequence: initial bacterial colonization, followed by SCFA production enhancement, then gradual introduction of diverse substrates. This periodic approach maintains health reliability through controlled SCFA levels while progressively building microbiome complexity over time.
Solution Approach 2:
The patent changes parameters systematically by adjusting the types and amounts of oligosaccharides introduced at different stages. Initially focusing on substrates that promote acetate and lactate production for health reliability, then gradually introducing more complex oligosaccharide structures to enhance diversity, thereby transforming the microbiome from a simple to a complex state while maintaining health.
3Productivity
If specific bacterial strains are selected for growth on mammalian milk oligosaccharides, then SCFA production is improved, but the selection process increases device complexity
Solution Approach 1:
The patent applies self-service by selecting bacterial strains that naturally possess the capability to grow on mammalian milk oligosaccharides and produce SCFA. Rather than implementing complex external selection mechanisms, the system uses the inherent metabolic capabilities of specific bacterial species (Bifidobacterium, Lactobacillus, Streptococcus) to self-select and thrive on the provided substrates, simplifying the selection process while maintaining high SCFA production.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the health of the infant microbiome, reducing pathogenic bacteria by up to 85%, lowering antibiotic resistance genes by up to 85%, and significantly increasing SCFA levels, thereby improving stool consistency and reducing inflammation.
Implementation Method 1
bacterial strains selected for their growth on mammalian milk oligosaccharides... increase output of acetate and lactate
Data Source
AI summary
The inventions described herein relate generally to the use of compositions to increase output of acetate and lactate while reducing pH and the levels of pathogenic bacteria and inflammation in the gut of a nursing infant mammal including humans. These compositions generally comprise one or more bacterial strains selected for their growth on mammalian milk oligosaccharides, a source of mammalian milk oligosaccharides, and, optionally, nutritive components required for the growth of that infant mammal.